GTERD
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🍃 Esg
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual capital growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Great Western Exploration Limited - Rights - Applications Close 26-Mar-2020
📈 Performance
Price History
N/A
1M
All Time
Graph
Table
Performance graph isn't available yet for this share
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in GTERD
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in GTERD
N/A
GTERD investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in GTERD also invest in...
Want more shares? Try these...
Genetic Technologies Ltd. is a molecular diagnostics company, which engages in the provision of molecular risk assessment tests for cancer. The company is headquartered in Melbourne, Victoria and currently employs 52 full-time employees. The firm offers predictive genetic testing and risk assessment tools. The firm is engaged in providing genomics-based tests on health, wellness and serious disease through its GeneType and EasyDNA brands. The firm operates through three segments: EasyDNA, AffinityDNA, and geneType / Corporate. The EasyDNA segment relates to EasyDNA branded test sales and expenses. The AffinityDNA segment relates to AffinityDNA branded test sales and expenses. The geneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and type two diabetes in a single test. GeneType also offers integrated risk testing for a range of serious conditions. EasyDNA and AffinityDNA offer deoxyribonucleic acid (DNA) testing services.
📊 Share price
